Home > News > Invitrogen and Signalomics agree nanotechnology diagnostics deal
April 20th, 2006
Invitrogen and Signalomics agree nanotechnology diagnostics deal
Abstract:
Invitrogen and Signalomics have agreed terms to develop nanotechnology-based laboratory approaches to cancer diagnostics in a move that is set to make the identification of tumours easier and quicker. Signalomics has become prominent in the nanocrystal field, becoming one of the first to develop a nanobiotechnology-based in vivo diagnostics platform by coupling designer proteins with fluorescent semiconductor crystals. These nanocrystal-protein conjugates, which are only a few millionths of a millimetre in size and are extremely photostable, can be targeted to faulty signalling proteins that are expressed in tumour tissue.
Source:
outsourcing-pharma.com
Related News Press |
Possible Futures
Nanoscale CL thermometry with lanthanide-doped heavy-metal oxide in TEM March 8th, 2024
Investments/IPO's/Splits
Daikin Industries becomes OCSiAl shareholder July 27th, 2021
INBRAIN Neuroelectronics raises over €14M to develop smart graphene-based neural implants for personalised therapies in brain disorders March 26th, 2021
180 Degree Capital Corp. Issues Second Open Letter to the Board and Shareholders of Enzo Biochem, Inc. March 26th, 2021
Nanomedicine
High-tech 'paint' could spare patients repeated surgeries March 8th, 2024
Researchers develop artificial building blocks of life March 8th, 2024
Announcements
What heat can tell us about battery chemistry: using the Peltier effect to study lithium-ion cells March 8th, 2024
Nanoscale CL thermometry with lanthanide-doped heavy-metal oxide in TEM March 8th, 2024
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||